Citation Impact
Citing Papers
Sensitization of Human Carcinoma Cells to Alkylating Agents by Small Interfering RNA Suppression of 3-Alkyladenine-DNA Glycosylase
2005 StandoutNobel
Protein Misfolding, Amyloid Formation, and Human Disease: A Summary of Progress Over the Last Decade
2017 Standout
Radioimmunodetection of amyloid deposits in patients with AL amyloidosis
2010
Structural Classification of Toxic Amyloid Oligomers
2008
Microbial manipulation of the amyloid fold
2012
Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
2008 StandoutNature
Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients
2002
Cancer to bone: a fatal attraction
2011 Standout
Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology
2020 Standout
AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils
2012
Amyloid diseases of the heart: current and future therapies
2012
Probing the origins, diagnosis and treatment of amyloid diseases using antibodies
2004
Distinct substrate preference of human and mouse N-methylpurine-DNA glycosylases
1996
Chemical Typing of Amyloid Protein Contained in Formalin-Fixed Paraffin-Embedded Biopsy Specimens
2001
Animal models of human amyloidoses: Are transgenic mice worth the time and trouble?
2009
Immune attack: the role of inflammation in Alzheimer disease
2015 Standout
Inhibition of Amyloid Formation
2012
Protein aggregation and neurodegenerative disease
2004 Standout
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers
2007
Decrease in immunoglobulin free light chains in patients with rheumatoid arthritis upon rituximab (anti-CD20) treatment correlates with decrease in disease activity
2010
Amyloidosis
2013
Renal Monoclonal Immunoglobulin Deposition Disease
2001
Systemic amyloidosis
2015 Standout
Annular Protofibrils Are a Structurally and Functionally Distinct Type of Amyloid Oligomer
2008
Normal and Pathologic Concentrations of Uremic Toxins
2012 Standout
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis
2012
The Amyloid State of Proteins in Human Diseases
2012 Standout
Alzheimer's disease: strategies for disease modification
2010
Improved anti-IgG and HSA affinity ligands: Clinical application of VHH antibody technology
2007
Amyloidosis: new strategies for treatment
2003
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
2013 Standout
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
2012 Standout
The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies
2004
The amyloid state and its association with protein misfolding diseases
2014 Standout
Molecular Mechanisms of Amyloidosis
2003 Standout
Systemic AA Amyloidosis
2012
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Analysis of Vλ-Jλ expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r(λIII) as a new amyloid-associated germline gene segment
2002
Epigallocatechin-3-gallate rapidly remodels PAP85-120, SEM1(45-107), and SEM2(49-107) seminal amyloid fibrils
2015 StandoutNobel
Protein Misfolding, Functional Amyloid, and Human Disease
2006 Standout
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
2002 Standout
Conformational Abs recognizing a generic amyloid fibril epitope
2002
Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils
2007
Copper Homeostasis and Neurodegenerative Disorders (Alzheimer's, Prion, and Parkinson's Diseases and Amyotrophic Lateral Sclerosis)
2006 Standout
Autologous stem cell transplantation for primary systemic amyloidosis
2002
A novel membrane antigen selectively expressed on terminally differentiated human B cells
1994
Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion
2004
Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis
2003 StandoutScience
Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4.
2003
Nanobodies: Natural Single-Domain Antibodies
2013 Standout
Works of D Wolfenbarger being referenced
Production and Immunodiagnostic Applications of Antihuman Light Chain Monoclonal Antibodies
1993
Preferential Expression of Human λ-Light-Chain Variable-Region Subgroups in Multiple Myeloma, AL Amyloidosis, and Waldenström's Macroglobulinemia
1994
Antibody-Mediated Resolution of Light Chain-Associated Amyloid Deposits
2000
Differences in kappa to lambda (κ:λ) ratios of serum and urinary free light chains
1998